Imunon, Inc. IMNN

IMNN Company Overview

Imunon, Inc. is a U.S.-based clinical-stage biotechnology company focused on developing nucleic acid-based immunotherapies and next-generation non-viral DNA delivery technologies. The company operates primarily in the oncology and infectious disease sectors, with research centered on DNA-mediated immunotherapy, cytokine-based cancer treatments, and vaccine delivery systems. Imunon’s core platform technologies include its proprietary TheraPlas and PlaCCine delivery systems, which are designed to enhance cellular uptake and expression of DNA-based therapeutics. The company’s primary revenue sources historically have included research collaborations, grants, and capital market financing, as it remains in the clinical development stage without approved commercial products.

The company was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in 2022 to reflect its strategic transition toward immunotherapy and DNA-based therapeutics. Its lead clinical candidate, IMNN-001, is being evaluated for the treatment of advanced ovarian cancer through localized IL-12 immunotherapy delivered via the company’s proprietary platform. Imunon positions itself within the biotechnology sector as a developer of non-viral gene-based therapies intended to improve immune activation while reducing systemic toxicity associated with conventional cancer therapies.